2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1876

Influence of Alcohol Consumption on the Risk of SLE Among Women in the Nurses’ Health Studies
Abstract Number: 680

Influence of Antimalarial doesn´t Modify the Outcome of Cytopenias in Systemic Lupus Erythematosus
Abstract Number: 393

Influence of Body Mass Index on Disease Activity and Radiographic Joint Damage in Rheumatoid Arthritis : A Systematic Review and Meta-Analysis
Abstract Number: 1663

Influence of Ethnicity on Efficacy of Current Immunosuppressive Protocols in Proliferative Lupus Nephritis
Abstract Number: 1431

Influence of Radiographic Joint Damage in Mortality Risk in a Cohort of Rheumatoid Arthritis Patients: A 20 Years Survival Study
Abstract Number: 777

Influence of the IL17A Locus in Giant Cell Arteritis Susceptibility
Abstract Number: 74

Influence of the Polymorphism IL1ß (-511 A/C) and IL6 (- 174 G/C) on the Activity, Radiographic Damage and Clinical Forms of Patients with Psoriatic Arthritis (PSA)
Abstract Number: 1489

Influences of Disease Activity at the Initiation of Iguratimod, a Small Molecule Antirheumatic Drug, on Efficacy of Iguratimod in Patients with Rheumatoid Arthritis –a Multicenter Registry Study-
Abstract Number: 648

Influenza A (H1N1) Virus Infection Triggers Severe Pulmonary Inflammation in Lupus-Prone Mice Following Viral Clearance
Abstract Number: 30

Inhibiting Autocrine Interleukin-6 (IL-6) Trans-Signalling in Human CD14^+VE Monocultures Reduces Osteoclast Differentiation
Abstract Number: 651

Inhibiting Tweak (TNF-like weak inducer of apoptosis) Signaling Improves Blood Brain Barrier Integrity and Protects from Neuronal Damage in Murine Neuropsychiatric Lupus
Abstract Number: 860

Inhibition of G Protein βγ Signaling Inhibits Nephritis in Lupus Prone Mice
Abstract Number: 311

Inhibition of Natural Killer (NK) Cell Cytotoxicity By Interleukin-6 (IL-6): Implications for the Pathogenesis of Macrophage Activation Syndrome
Abstract Number: 2917

Inhibition of PAD4 Activity and the Formation of Neutrophil Extracellular Traps Via PTPN22, but Not Its Rheumatoid Arthritis-Prone W620 Variant
Abstract Number: 2320

Initial Benchmarking of the Quality of Medical Care of Childhood-Onset Systemic Lupus Erythematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].